Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck Kgaa ADR (OP: MKKGY )

29.89 +0.03 (+0.10%)
Streaming Delayed Price Updated: 12:58 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck Kgaa ADR

Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisition
Pfizer Inc (NYSE: PFE)  
Via Benzinga
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis
Merck KGaA (OTC: MKGAF) (OTC:  
Via Benzinga
Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors
Repligen Corporation (NASDAQ: RGEN) agreed to acquire Sweden-based privately-held Metenova.  
Via Benzinga
Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023
Merck KGa Germany (OTC: MKGAF) (OTC: MKKGY) reported  
Via Benzinga
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List
The World Health Organization (WHO) published the new editions of the Model Lists of Essential Medicines (EML) and Essen 
Via Benzinga
Germany's Merck To Launch Semiconductor Base In China
Via Benzinga
Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation
RBC Capital Markets has downgraded Abcam PLC (NASDAQ: ABCM) from Outperform to Sector Perform with a price target of $22,  
Via Benzinga
Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions
Via Benzinga
FDA Issues Partial Clinical Hold On Merck Germany's Multiple Sclerosis Study
Via Benzinga
Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer
Via Benzinga
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
Via Benzinga
With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics
Via Benzinga
PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment
Via Benzinga
Mersana Inks Cancer Therapy Development Deal With Merck Germany
Via Benzinga
SpaceX Starlink's New In-Flight Connectivity Service, Amazon's NY Workers Reject Union, Celsius Network Faces Several Federal Investigations: Top Stories Wednesday, Oct. 19
Reuters US Lawmakers Plan Hearing On Kroger, Albertsons' $25B Merger 
Via Benzinga
Germany's Merck Slapped With Formal French Investigation Related To Its Thyroid Drug
The French court is reportedly investigating Germany-based Merck KGaA (OTC: MKKGY), saying the company provided misleading information regarding its thyroid drug product Levothyrox. 
Via Benzinga
PDS Biotech Highlights Expanded Data From PDS0101 Triple Combination Trial In HPV-Positive Cancers
Via Benzinga
TSM Looks To Hire Over 8,000 People In 2022
Taiwan’s top two chipmakers plan to hire over 10,000 engineers in 2022 to bolster their aggressive expansion plans and maintain their technological edge, Financial... 
Via Benzinga
Despite Palantir’s Impressive Deals, Its Losses and Valuation Make It Unappetizing
Amid continued questions about the profitability and the competitive advantages of Palantir in a crowded field, PLTR stock remains a sell. 
Via InvestorPlace
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia... 
Via Benzinga
GlaxoSmithKline, Merck KGaA End $4B Cancer Drug Pact
Merck KGaA (OTC: MKGAF) and GlaxoSmithKline Plc (NASDAQ: GSK) have ended their $4 billion collaboration on cancer treatment, bintrafusp alfa. Merck said... 
Via Benzinga
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE... 
Via Benzinga
Merck KGaA Pulls Plug On GSK-Partnered Cancer Drug Trial
Merck KGaA's (OTC: MKGAF) announced that a Phase 2 trial of bintrafusp alfa had been discontinued, as an independent data monitoring committee has determined the... 
Via Benzinga
Sutro Biopharma Receives Undisclosed Milestone Payment Under Bispecific ADC Collaboration with Merck
Sutro Biopharma Inc (NASDAQ: STRO) has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA... 
Via Benzinga
Immutep, Merck Germany Team Up for Eftilagimod/Bintrafusp Combo Trial In Solid Tumors
Immutep Limited (NASDAQ: IMMP) has announced a new collaboration and supply agreement with Germany-based Merck KGaA (OTC: MKGAF) for a Phase 1/2a INSIGHT... 
Via Benzinga
Gene Therapy Player Vera Therapeutics Prices IPO Well Below Range At $11/Share
Vera Therapeutics Inc has priced its 4.35 million share IPO at $11 per share, well below its targeted range of $14 to $16, raising $47.58 million in gross proceeds. The... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
MERCK KGAA (MKKGY) Q1 2021 Earnings Call Transcript
MKKGY earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
UK's NICE Provisionally Rejects Coverage Of Pfizer-Merck KGaA's Bavencio As First-Line Therapy For Bladder Cancer
England’s drug-cost watchdog has shown a cold-shoulder to Pfizer Inc (NYSE: PFE) and Merck KGaA’s (OTCMKTS: MKGAF) Bavencio (avelumab) as... 
Via Benzinga
The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8) Aclaris Therapeutics, Inc... 
Via Benzinga
Novartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio
Novartis AG (NYSE: NVS) has struck a deal with UK-based Artios Pharma to access DNA damage response (DDR) targets that can potentially enhance its radioligand... 
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.